Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Public ClinicalTrials.gov record NCT00206726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, Phase II, open label trial evaluating the efficacy and safety of alemtuzumab and fludarabine in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) patients who have received at least one prior therapy. Treatments will be administered on a 28-day cycle for 4-6 cycles, with an evaluation during Cycle 4 to permit re-staging. Alemtuzumab and fludarabine will be administered on Days 1-5 of each cycle. Patients will be assessed for response at the time of re-staging at Cycle 4 and at the end of Cycle 6. At the time of the re-staging, patients achieving a Partial Remission (PR) or Stable Disease (SD) will be given an additional 2 cycles of treatment and patients demonstrating presumptive signs of a Complete Remission (CR) will receive no further treatment but will be followed for response.
Study identification
- NCT ID
- NCT00206726
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Aug 28, 2016
2005 – 2008
United States locations
- U.S. sites
- 27
- U.S. states
- 21
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35223 | — |
| Not listed | Berkeley | California | 94704 | — |
| Not listed | Burbank | California | 91595 | — |
| Not listed | Concord | California | 94520 | — |
| Not listed | Stanford | California | 94305-5118 | — |
| Not listed | Washington D.C. | District of Columbia | 20422 | — |
| Not listed | Lakeland | Florida | 33805 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Aurora | Illinois | 60504 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Springfield | Illinois | 62703 | — |
| Not listed | Metairie | Louisiana | 70006 | — |
| Not listed | Clinton | Maryland | 20735 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Jackson | Michigan | 39202 | — |
| Not listed | Minneapolis | Minnesota | 55417 | — |
| Not listed | Reno | Nevada | 89520 | — |
| Not listed | Lebanon | New Hampshire | 03756-0001 | — |
| Not listed | New Brunswick | New Jersey | 08903-2681 | — |
| Not listed | Albany | New York | 12208-3473 | — |
| Not listed | Northport | New York | 11768 | — |
| Not listed | Lawton | Oklahoma | 73505 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Pittsburgh | Pennsylvania | 15224 | — |
| Not listed | Johnson City | Tennessee | 37604 | — |
| Not listed | Tacoma | Washington | 98431-5000 | — |
| Not listed | Milwaukee | Wisconsin | 53226-3596 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00206726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2016 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00206726 live on ClinicalTrials.gov.